Andrew SchachterFounder and CEO at Axiom Real-Time Metrics
As Founder and CEO of Axiom Real-Time Metrics, Andrew Schachter delivers the visionary leadership integral to the company’s almost 20 years of eClinical technology and Managed services success.
The pairing of his expertise and deep knowledge of clinical research with his passion for enabling smarter and faster clinical studies has been critical to Axiom’s growth into a recognized innovator and leader in the Small-to-Medium life science eClinical solutions space.
Axiom has been at the forefront of managing complex clinical studies, inclusive recently of over ½ dozen programs around COVID-19 treatments and vaccines. The team at Axiom has been working on COVID-19 studies in early March, when it partnered with Oxford University on a global COVID-19 program. These research efforts across multiple clients has been planned, configured and launched in record time as part of a global effort to find solutions to COVID-19. This study includes over a dozen countries participating in the collection of ePRO based daily COVID-19 symptoms tracking across 40,000 patients